Ha Eun-Sol, Park Heejun, Jeong Ji-Su, Lee Seon-Kwang, Kang Hui-Taek, Baek In-Hwan, Kim Min-Soo
College of Pharmacy and Research Institute for Drug Development, Pusan National University, 63 Busandaehak-ro, Geumjeong-gu, Busan 46241, Republic of Korea.
College of Pharmacy, Duksung Women's University, 33, Samyangro 144-gil, Dobong-gu, Seoul 01369, Republic of Korea.
Pharmaceutics. 2024 Nov 24;16(12):1508. doi: 10.3390/pharmaceutics16121508.
This study investigates the impact of supercritical antisolvent (SAS) process parameters on the particle formation of telmisartan, a poorly water-soluble drug. A fractional factorial design was employed to examine the influence of the SAS process parameters, including solvent ratio, drug solution concentration, temperature, pressure, injection rate of drug solution, and CO₂ flow rate, on particle formation. Solid-state characterizations of the SAS process particles using XRD and FT-IR confirmed their amorphous nature. The effect of particle size on the kinetic solubility, dissolution, and oral bioavailability of telmisartan was also assessed. Using a mixture of dichloromethane and methanol, telmisartan amorphous nano-microparticles with sizes between 200 and 2000 nm were produced. The key parameters, particularly drug solution concentration and temperature, significantly affected the particle size. Interestingly, the ratio of the solvent mixture also had a significant effect on the particle morphology. Further experiments were performed to determine the conditions for preparing telmisartan amorphous nano-microparticles with various sizes by controlling the solvent mixture ratio and the concentration of the drug solution. It was revealed that a reduction in the amorphous particle size enhanced both the kinetic solubility and dissolution rates, leading to a significantly increased in vivo oral bioavailability in rats compared to unprocessed telmisartan. These findings suggest that SAS processing, utilizing adjustments of process parameters, offers an effective strategy for enhancing the bioavailability of poorly soluble drugs by generating amorphous spherical nano-microparticles with optimized particle size.
本研究考察了超临界抗溶剂(SAS)工艺参数对替米沙坦(一种难溶性药物)颗粒形成的影响。采用分数析因设计来研究SAS工艺参数,包括溶剂比、药物溶液浓度、温度、压力、药物溶液注射速率和CO₂流速,对颗粒形成的影响。使用X射线衍射(XRD)和傅里叶变换红外光谱(FT-IR)对SAS工艺颗粒进行固态表征,证实了它们的无定形性质。还评估了粒径对替米沙坦的动力学溶解度、溶出度和口服生物利用度的影响。使用二氯甲烷和甲醇的混合物,制备出了尺寸在200至2000纳米之间的替米沙坦无定形纳米微粒。关键参数,特别是药物溶液浓度和温度,对粒径有显著影响。有趣的是,溶剂混合物的比例对颗粒形态也有显著影响。通过控制溶剂混合物比例和药物溶液浓度,进一步开展实验以确定制备不同尺寸替米沙坦无定形纳米微粒的条件。结果表明,与未处理的替米沙坦相比,无定形颗粒尺寸的减小提高了动力学溶解度和溶出速率,导致大鼠体内口服生物利用度显著增加。这些研究结果表明,通过调整工艺参数的SAS工艺,通过生成具有优化粒径的无定形球形纳米微粒,为提高难溶性药物的生物利用度提供了一种有效策略。